Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival.

Werstein B, Dunlap J, Cascio MJ, Ohgami RS, Fan G, Press R, Raess PW.

J Mol Diagn. 2019 Dec 19. pii: S1525-1578(19)30454-4. doi: 10.1016/j.jmoldx.2019.11.004. [Epub ahead of print]

PMID:
31866570
2.

Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells: A Diagnostic Mimicker of Other Malignant and Reactive Entities.

Hoffmann JC, Lin CY, Bhattacharyya S, Weinberg OK, Chisholm KM, Bayerl M, Cascio M, Venkataraman G, Allison K, Troxell M, Chang CC, Bagg A, George TI, O'Malley D, Ohgami RS.

Am J Surg Pathol. 2019 Dec;43(12):1653-1660. doi: 10.1097/PAS.0000000000001347.

PMID:
31436555
3.

Indolent In Situ B-Cell Neoplasms With MYC Rearrangements Show Somatic Mutations in MYC and TNFRSF14 by Next-generation Sequencing.

Kumar J, Butzmann A, Wu S, Easly S, Zehnder JL, Warnke RA, Bangs CD, Jangam D, Cherry A, Lau J, Nybakken G, Ohgami RS.

Am J Surg Pathol. 2019 Dec;43(12):1720-1725. doi: 10.1097/PAS.0000000000001338.

PMID:
31368914
4.

Molecular genetic testing methodologies in hematopoietic diseases: current and future methods.

Sridhar K, Singh A, Butzmann A, Jangam D, Ohgami RS.

Int J Lab Hematol. 2019 May;41 Suppl 1:102-116. doi: 10.1111/ijlh.13024. Review.

PMID:
31069972
5.

Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.

Thauland TJ, Pellerin L, Ohgami RS, Bacchetta R, Butte MJ.

Front Immunol. 2019 Apr 12;10:753. doi: 10.3389/fimmu.2019.00753. eCollection 2019.

6.

Expounding on the essence of epigenetic and genetic abnormalities in blastic plasmacytoid dendritic cell neoplasms.

Lezama L, Ohgami RS.

Haematologica. 2019 Apr;104(4):642-643. doi: 10.3324/haematol.2018.211557. No abstract available.

7.

Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.

Li P, Shahmarvand N, Lynch D, Gotlib JR, Merker JD, Zehnder JL, George TI, Ohgami RS.

Int J Lab Hematol. 2019 Jun;41(3):345-352. doi: 10.1111/ijlh.12981. Epub 2019 Feb 27.

PMID:
30811101
8.

Super-Resolution Digital Pathology Image Processing of Bone Marrow Aspirate and Cytology Smears and Tissue Sections.

Singh A, Ohgami RS.

J Pathol Inform. 2018 Dec 24;9:48. doi: 10.4103/jpi.jpi_56_18. eCollection 2018.

9.

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.

Farris M, Hughes RT, Lamar Z, Soike MH, Menke JR, Ohgami RS, Winkfield K.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e1-e8. doi: 10.1016/j.clml.2018.10.004. Epub 2018 Oct 13. Review.

PMID:
30396823
10.

An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping.

Lau H, Nagy A, Atwater SK, Cascio MJ, Ohgami RS.

Int J Lab Hematol. 2018 Dec;40(6):715-720. doi: 10.1111/ijlh.12909. Epub 2018 Jul 31.

PMID:
30066366
11.

Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis.

Gars E, Purington N, Scott G, Chisholm K, Gratzinger D, Martin BA, Ohgami RS.

Haematologica. 2018 Oct;103(10):1635-1641. doi: 10.3324/haematol.2017.186627. Epub 2018 Jun 14. No abstract available.

12.

An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality.

Sumarriva Lezama L, Chisholm KM, Carneal E, Nagy A, Cascio MJ, Yan J, Chang CC, Cherry A, George TI, Ohgami RS.

Histopathology. 2018 Nov;73(5):767-776. doi: 10.1111/his.13668. Epub 2018 Aug 6.

PMID:
29884995
13.

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, Mughal T, Ali S, Ohgami RS.

Blood Adv. 2018 Mar 13;2(5):481-491. doi: 10.1182/bloodadvances.2017009654.

14.

Mutations in the signal transducer and activator of transcription family of genes in cancer.

Shahmarvand N, Nagy A, Shahryari J, Ohgami RS.

Cancer Sci. 2018 Apr;109(4):926-933. doi: 10.1111/cas.13525. Epub 2018 Mar 2. Review.

15.

Next-Generation Sequencing for Lymphomas: Perfecting a Pipeline for Personalized Pathobiologic and Prognostic Predictions.

Ohgami RS, Rosenwald A, Bagg A.

J Mol Diagn. 2018 Mar;20(2):163-165. doi: 10.1016/j.jmoldx.2018.01.002. Epub 2018 Feb 2.

16.

A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.

Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD.

Cancer Genet. 2017 Oct;216-217:10-15. doi: 10.1016/j.cancergen.2017.05.001. Epub 2017 May 10.

PMID:
29025582
17.

Case Report: Clinical Variation in Children With Thrombopoietin Receptor (C-MPL) Mutations: Report of 2 Cases.

Lo C, Alvarez E, Ohgami RS, Jeng M.

J Pediatr Hematol Oncol. 2018 Jan;40(1):67-70. doi: 10.1097/MPH.0000000000000944.

PMID:
28859041
18.

Hematolymphoid lesions of the breast.

Hoffmann J, Ohgami RS.

Semin Diagn Pathol. 2017 Sep;34(5):462-469. doi: 10.1053/j.semdp.2017.05.007. Epub 2017 May 28. Review.

PMID:
28662998
19.

Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia.

Kunder C, Cascio MJ, Bakke A, Venkataraman G, O'Malley DP, Ohgami RS.

Am J Clin Pathol. 2017 Jun 1;147(6):596-603. doi: 10.1093/ajcp/aqx034.

PMID:
28575178
20.

A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.

Shahmarvand N, Oak JS, Cascio MJ, Alcasid M, Goodman E, Medeiros BC, Arber DA, Zehnder JL, Ohgami RS.

Int J Lab Hematol. 2017 Aug;39(4):375-383. doi: 10.1111/ijlh.12636. Epub 2017 Apr 19.

PMID:
28422420
21.
22.

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.

Alcasid M, Ma L, Gotlib JR, Arber DA, Ohgami RS.

Int J Lab Hematol. 2017 Apr;39(2):129-136. doi: 10.1111/ijlh.12594. Epub 2017 Jan 30.

PMID:
28133918
23.

Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations.

Oak JS, Ohgami RS.

Curr Med Res Opin. 2017 Apr;33(4):781-782. doi: 10.1080/03007995.2017.1284049. Epub 2017 Feb 3. No abstract available.

PMID:
28097878
24.
25.

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA.

Sci Transl Med. 2016 Nov 9;8(364):364ra155.

26.

Primary lymphoma of bone in the pediatric and young adult population.

Chisholm KM, Ohgami RS, Tan B, Hasserjian RP, Weinberg OK.

Hum Pathol. 2017 Feb;60:1-10. doi: 10.1016/j.humpath.2016.07.028. Epub 2016 Aug 20.

PMID:
27554207
27.

A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma.

Ozawa MG, Bhaduri A, Chisholm KM, Baker SA, Ma L, Zehnder JL, Luna-Fineman S, Link MP, Merker JD, Arber DA, Ohgami RS.

Mod Pathol. 2016 Oct;29(10):1212-20. doi: 10.1038/modpathol.2016.102. Epub 2016 Jun 24.

28.

Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance.

Fernandez-Pol S, Ma L, Ohgami RS, Arber DA.

Mod Pathol. 2016 Sep;29(9):996-1003. doi: 10.1038/modpathol.2016.100. Epub 2016 Jun 3.

29.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists.

Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print] No abstract available.

PMID:
27081879
30.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists.

Arch Pathol Lab Med. 2016 Nov;140(11):1225-1227. Epub 2016 Apr 15. No abstract available.

PMID:
27081876
31.

An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.

Hoffmann JC, Chisholm KM, Cherry A, Chen J, Arber DA, Natkunam Y, Warnke RA, Ohgami RS.

Hum Pathol. 2016 Feb;48:9-17. doi: 10.1016/j.humpath.2015.09.033. Epub 2015 Oct 23.

PMID:
26772393
32.

Surface Light Chain Expression in Primary Mediastinal Large B-Cell Lymphomas by Multiparameter Flow Cytometry.

Weinberg OK, Rodig SJ, Pozdnyakova O, Ren L, Arber DA, Ohgami RS.

Am J Clin Pathol. 2015 Oct;144(4):635-41. doi: 10.1309/AJCP3Q1DHWKCQRWY.

PMID:
26386085
33.

Indolent T-lymphoblastic proliferation: a name with specific meaning.

Ohgami RS, Natkunam Y, Warnke RA.

Hum Pathol. 2015 Nov;46(11):1785-6. doi: 10.1016/j.humpath.2015.07.026. Epub 2015 Aug 11. No abstract available.

PMID:
26363525
34.

Cytogenetic Variation of B-Lymphoblastic Leukemia With Intrachromosomal Amplification of Chromosome 21 (iAMP21): A Multi-Institutional Series Review.

Johnson RC, Weinberg OK, Cascio MJ, Dahl GV, Mitton BA, Silverman LB, Cherry AM, Arber DA, Ohgami RS.

Am J Clin Pathol. 2015 Jul;144(1):103-12. doi: 10.1309/AJCPLUYF11HQBYRB.

PMID:
26071468
35.

The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia.

Ohgami RS, Arber DA.

Int J Lab Hematol. 2015 May;37 Suppl 1:122-32. doi: 10.1111/ijlh.12367. Review.

PMID:
25976970
36.

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani RH, Levy R, Hicks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA.

Blood. 2015 Jun 11;125(24):3679-87. doi: 10.1182/blood-2015-03-635169. Epub 2015 Apr 17.

37.

Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry.

Chisholm KM, Merker JD, Gotlib JR, Gitana G, Lefterova M, Zehnder JL, George TI, Arber DA, Ohgami RS.

Am J Clin Pathol. 2015 Apr;143(4):527-34. doi: 10.1309/AJCPZ3J4GEEYIRRA.

PMID:
25780004
38.

The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma.

Karnik T, Ozawa MG, Lefterova M, Luna-Fineman S, Alvarez E, Link M, Zehnder JL, Arber DA, Ohgami RS.

Hum Pathol. 2015 Apr;46(4):629-33. doi: 10.1016/j.humpath.2014.12.016. Epub 2015 Jan 29.

PMID:
25701230
39.

Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.

Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, Elvin JA, Palma NA, Erlich R, Vergilio JA, Chmielecki J, Ross JS, Stephens PJ, Hermann R, Miller VA, Miles CR.

Blood Cancer J. 2015 Feb 6;5:e278. doi: 10.1038/bcj.2014.95. No abstract available.

40.

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.

Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA.

Mod Pathol. 2015 May;28(5):706-14. doi: 10.1038/modpathol.2014.160. Epub 2014 Nov 21.

41.

Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings.

Weinberg OK, Ohgami RS, Ma L, Seo K, Ren L, Gotlib JR, Seetharam M, Cherry A, Arber DA.

Am J Clin Pathol. 2014 Aug;142(2):190-5. doi: 10.1309/AJCPMLO84JDNVLNK.

PMID:
25015859
42.

Large B-cell lymphomas poor in B cells and rich in PD-1+ T cells can mimic T-cell lymphomas.

Ohgami RS, Zhao S, Natkunam Y.

Am J Clin Pathol. 2014 Aug;142(2):150-6. doi: 10.1309/AJCPFJWKQ6GTVQE6.

PMID:
25015854
43.

STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.

Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA.

Haematologica. 2014 Jul;99(7):e105-7. doi: 10.3324/haematol.2013.101543. Epub 2014 May 16. No abstract available.

44.

E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms.

Ohgami RS, Chisholm KM, Ma L, Arber DA.

Am J Clin Pathol. 2014 May;141(5):656-64. doi: 10.1309/AJCP8M4QQTAZPGRP.

PMID:
24713736
45.

Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression.

Ohgami RS, Sendamarai AK, Atwater SK, Liedtke M, Fleming MD, Natkunam Y, Warnke RA.

Am J Surg Pathol. 2014 Sep;38(9):1298-304. doi: 10.1097/PAS.0000000000000197.

PMID:
24618611
46.

Challenges in Consolidated Reporting of Hematopoietic Neoplasms.

Ohgami RS, Arber DA.

Surg Pathol Clin. 2013 Dec;6(4):795-806. doi: 10.1016/j.path.2013.08.001. Epub 2013 Oct 18.

PMID:
26839198
47.

Profound plasmacytosis in a patient with dengue.

Ewalt MD, Abeynayake J, Waggoner JJ, Pinsky BA, Ohgami RS.

Int J Hematol. 2013 Nov;98(5):518-9. doi: 10.1007/s12185-013-1452-3. Epub 2013 Oct 11. No abstract available.

PMID:
24114365
48.

Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma.

Ohgami RS, Arber DA, Zehnder JL, Natkunam Y, Warnke RA.

Adv Anat Pathol. 2013 May;20(3):137-40. doi: 10.1097/PAP.0b013e31828d17ec. Review.

PMID:
23574769
49.

STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia.

Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA.

Leukemia. 2013 Nov;27(11):2244-7. doi: 10.1038/leu.2013.104. Epub 2013 Apr 8. No abstract available.

PMID:
23563237
50.

TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma.

Ohgami RS, Zhao S, Ohgami JK, Leavitt MO, Zehnder JL, West RB, Arber DA, Natkunam Y, Warnke RA.

Am J Surg Pathol. 2012 Nov;36(11):1619-28. doi: 10.1097/PAS.0b013e318264e223.

PMID:
23060347

Supplemental Content

Loading ...
Support Center